Healthcare
Poolbeg Pharma PLC(POLBF)
Live Price
Offline$0.0919
+0.00% today
1Y Change
+118.81%
Window
Jun 20, 2025 → Jun 16, 2026
- Market Cap
- $30.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -46.8%
- Dividend Yield
- 0.0%
Coverage: 253 bars · Jun 20, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Poolbeg Pharma PLC (POLBF) is a Healthcare stock with a market cap of $30.00M and listed on OTC. The stock last traded around $0.09 and up 118.8% across the available one-year price window (Jun 20, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -46.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -46.8%, free cash flow -18.7% with operating margin 0.0% and ROIC -53.6%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines POLBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -46.8%, with operating margin around 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
POLBF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
POLBF Max Drawdown
-20.36%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for POLBF and SPY.
Company Overview
Poolbeg Pharma PLC
Other OTC
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
- Leadership
- Jeremy Skillington
- IPO Date
- Apr 1, 2022
- Employees
- 15
- Street Address
- Queen Mary BioEnterprises Innovation Ctr
- Mailing
- London, E1 2AX
- Region
- London, GB
- Reporting Currency
- USD
- Investor Line
- 44 20 7183 1499
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- —
- Price/Book
- 1.8
Growth
- Revenue
- 0.0%
- EPS
- -46.8%
- Free Cash Flow
- -18.7%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -53.9%
- ROIC
- -53.6%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 24.94
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.